Elanco Animal Health's Varenzin-CA1 Gets Conditional FDA Approval to Treat Anemia in Cats
May 01 2023 - 03:47PM
Dow Jones News
By Mary de Wet
Elanco Animal Health Inc. received conditional approval from the
Food and Drug Administration on Monday for its drug Varenzin-CA1 to
treat anemia in cats with chronic kidney disease.
The agency said Varenzin-CA1 helps to increase production of
erythropoietin in the kidney, which in turn stimulates the bone
marrow to produce more red blood cells.
The current treatments available for nonregenerative anemia in
cats with CKD include blood transfusion, supplemental iron therapy
and erythropoietin replacement, the FDA said.
Under conditional approval, the FDA has concluded that the drug
is safe for its intended purpose and has a reasonable expectation
of being effective. Cats suffering from the disease can receive the
treatment while full effectiveness data is being collected, the
agency said.
The initial conditional approval is valid for one year with the
potential for four annual renewals, the FDA said.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
May 01, 2023 15:32 ET (19:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Nov 2023 to Dec 2023
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Dec 2022 to Dec 2023
